Business · Companies · 2 hrs ago
Orthocell reports record US Remplir sales in October
Orthocell sold 92 Remplir units in the US in October, its strongest month since the product launched.
The sales brought in A$279,000 in revenue, and unit sales were 84% above the average of 50 per month in the first quarter of FY27.
Remplir is a collagen-based wrap used in peripheral nerve repair surgery.
It received US FDA clearance in April 2025, and Orthocell says its sales growth reflects more surgeons using it and wider access at hospitals.
The result matters because the company says Remplir is gaining traction in a large market where adoption of new medical technologies can take time.
Orthocell says it will expand surgeon and distributor networks and increase manufacturing capacity as it works to grow use of the product.
Orthocell reported record US sales of its Remplir nerve repair product in October.
The company sold 92 units, generating A$279,000 in revenue.
The unit sales were 84% above the average of 50 units per month in Q1 FY27.
Orthocell said growing surgeon adoption, repeat use, distributor activity and hospital access contributed to the result.
Remplir received US FDA 510(k) clearance in April 2025.
- Who
- Orthocell, an Australian medical technology company.
- What
- It sold a record 92 units of its Remplir nerve repair product in the US in October, generating A$279,000 in revenue.
- When
- October; the year is not stated.
- Where
- The United States.
- Why
- Orthocell attributed the result to factors including growing surgeon adoption, increased repeat use, more active distributor representatives and expanded hospital access.
This story does not have two clearly opposing sides.
Remplir received FDA 510(k) clearance.
Orthocell recorded average monthly US sales of 50 units.
Orthocell sold 92 Remplir units in the US, generating A$279,000 in revenue.
Stockhead published its report on Orthocell’s record monthly US sales.
- October US sales
- 92 units
- October revenue
- A$279,000
- Increase over Q1 FY27 monthly average
- 84%
- Q1 FY27 average monthly sales
- 50 units
- FDA 510(k) clearance
- April 2025
What people are saying
The improvement in key commercial indicators demonstrates that Remplir is gaining traction in the US market
While establishing a new medical technology in a large market takes time and sustained effort, our focus remains on accelerating surgeon adoption, expanding hospital access and increasing product utilisation.
Orthocell has invested in the commercial infrastructure required to support Remplir’s expansion and is continuing to expand its manufacturing capacity in anticipation of increased demand
The board remains confident in the product’s significant U.S. market potential and the company’s strategy to translate growing market adoption into long-term commercial success.